Search terms
Results 1 - 8 of 8 - ordered by :

OSLER-1 and OSLER-2 Clinical Trials Evolocumab, a monoclonal antibody that inhibits pro-protein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) ...

Date : 21/10/2015

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart ...

Date : 27/08/2018

Treatment of coronary artery disease Effect of exercise on blood pressure Mechanisms of diabetes mellitus development Stroke prevention Assessing the risk of cardiovascular disease Treatment of ...

Date : 12/10/2017

Patients with five or more risk factors have the same stroke risk as patients with atrial fibrillation, according to research presented at the ESC Congress today by Dr Christine Benn Christiansen ...

Date : 31/08/2013

Stress-related pathophysiological changes, such as lowered arrhythmic threshold and increased sympathetic activation with related increases in blood pressure and heart rate, as well as ...

Date : 24/04/2018

Results in patients with coronary artery disease and in patients with peripheral artery disease >Link to session Hot Line - Late Breaking Clinical Trials 2 SPYRAL HTN OFF-MED: Assessment of the ...

Date : 20/07/2017

First multidisciplinary recommendations on management of arrhythmias in ACS patients The first multidisciplinary recommendations on the management of arrhythmias in patients with acute coronary ...

Date : 30/08/2014

Rivaroxaban for stroke or TIA prevention in heart failure patients with sinus rhythm The results of the Commander HF trial about the effects of low dose Rivaroxaban in combination with antiplatelet ...

Date : 08/08/2019